The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

The number of bird flu cases in Central Massachusetts is relatively low, compared to a swath of the state that runs from ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

In theory, Moderna will be launching roughly 10 new programs between now and 2028. The programs with the highest earning potential are its combination jab for COVID and influenza, and its ...

Moderna Inc. (MRNA) rose for a fourth day on Thursday to grow by 10.10 percent at $42.39 apiece as investors continued to snap up shares in the company following news that it bagged a new $590 ...

Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza and will soon be ready to discuss “next steps” with ...